Identification
NameDinutuximab
Accession NumberDB09077
TypeBiotech
GroupsApproved
Description

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Protein structureNo structure small
Related Articles
Protein chemical formulaC6422H9982N1722O2008S48
Protein average weight145000.0 Da
SequencesNot Available
Synonyms
Dinutuximab beta
Monoclonal antibody ch14.18
External IDs APN-311 / APN311 / ch14.18 / ch14.18-UTC
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
UnituxinInjection3.5 mg/mLIntravenousUnited Therapeutics2015-03-10Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII7SQY4ZUD30
CAS number1363687-32-4
Pharmacology
Indication

Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Structured Indications
Pharmacodynamics

In vitro dinutuximab binds to neuroblastoma tumour cells and mediates the lysis of tumour cells via cell-mediated and complement-mediated cytotoxicity.

Mechanism of action

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour.

TargetKindPharmacological actionActionsOrganismUniProt ID
Ganglioside GD2Small moleculeyes
inhibitor
Humannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distribution

The mean volume of distribution at steady state (Vdss) is 5.4 L

Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life

The terminal half-life is 10 days

Clearance

The clearance is 0.21 L/day and increases with body size

Toxicity

The most common (incidence 15 %) grade 3 or 4 treatment-related adverse events in dinutuximab compared with standard therapy recipients were neuropathic pain (52 vs. 6 %), fever without neutropenia (39 vs. 6 %), any in-fection (39 vs. 22 %), hypokalaemia (35 vs. 2 %), hypersensitivity reactions (25 vs. 1 %), hyponatraemia (23 vs. 4 %), elevation of alanine transferase levels (23 vs. 3 %) and hypotension (18 vs. 0 %). Based on its mechanism of action, dinutuximab may cause fetal harm when administered to a pregnant woman however, there are no studies in pregnant women and no reproductive studies in animals to inform the drug-associated risk. Non-clinical studies suggest that dinutuximab-induced neuropathic pain is mediated by binding of the antibody to the GD2 antigen located on the surface of peripheral nerve fibers and myelin and subsequent induction of cell- and complement-mediated cytotoxicity. In clinical trials, 114 (85%) patients treated in the dinutuximab/RA group experienced pain despite preĀ­-treatment with analgesics including morphine sulfate infusion. Severe (Grade 3) pain occurred in 68 (51%) patients in the dinutuximab/RA group compared to 5 (5%) patients in the RA group. Pain typically occurred during the dinutuximab infusion and was most commonly reported as abdominal pain, generalized pain, extremity pain, back pain, neuralgia, musculoskeletal chest pain, and arthralgia.

Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Dinutuximab.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dinutuximab.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Dinutuximab.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dinutuximab.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dinutuximab.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Dinutuximab.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dinutuximab.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Dinutuximab.Experimental
BarbitalBarbital may increase the hypotensive activities of Dinutuximab.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Dinutuximab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Belimumab.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dinutuximab.Approved
BepridilThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dinutuximab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Dinutuximab.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.Approved
BortezomibThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Dinutuximab.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dinutuximab.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bupivacaine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Dinutuximab.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dinutuximab.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dinutuximab.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dinutuximab.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.Approved
ClozapineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Conivaptan.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dinutuximab.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dinutuximab.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Desflurane.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dinutuximab.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dinutuximab.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Dinutuximab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dinutuximab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.Approved, Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.Approved
DuloxetineDinutuximab may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dinutuximab.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dinutuximab.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dinutuximab.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Fimasartan.Approved
FingolimodDinutuximab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Dinutuximab is combined with G17DT.Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Dinutuximab.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dinutuximab.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dinutuximab.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.Approved
IndoraminThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Indoramin.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Dinutuximab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Dinutuximab is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dinutuximab.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dinutuximab.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Dinutuximab.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dinutuximab.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.Approved
LacidipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Lacidipine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dinutuximab.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Levobupivacaine.Approved
LevodopaDinutuximab may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dinutuximab.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dinutuximab.Approved
MethohexitalMethohexital may increase the hypotensive activities of Dinutuximab.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dinutuximab.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dinutuximab.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dinutuximab.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dinutuximab.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.Approved
MorphineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Dinutuximab.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.Approved
NicorandilNicorandil may increase the hypotensive activities of Dinutuximab.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dinutuximab.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dinutuximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Obinutuzumab.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Dinutuximab.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dinutuximab.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Dinutuximab.Approved
OxprenololThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Dinutuximab.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Dinutuximab.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Dinutuximab.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Phentolamine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Dinutuximab.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.Approved
PrimidonePrimidone may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dinutuximab.Approved
RasagilineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dinutuximab.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Dinutuximab is combined with CDX-110.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Dinutuximab.Approved
RisperidoneDinutuximab may increase the hypotensive activities of Risperidone.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Dinutuximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sevoflurane.Approved, Vet Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dinutuximab.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.Approved
SRP 299The risk or severity of adverse effects can be increased when Dinutuximab is combined with SRP 299.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sufentanil.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dinutuximab.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Thioridazine.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dinutuximab.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.Approved
TofacitinibDinutuximab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dinutuximab.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dinutuximab.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Dhillon S: Dinutuximab: first global approval. Drugs. 2015 May;75(8):923-7. doi: 10.1007/s40265-015-0399-5. [PubMed:25940913 ]
  2. Ahmed M, Cheung NK: Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Epub 2013 Dec 1. [PubMed:24295643 ]
  3. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 1;51(1):144-9. [PubMed:1988079 ]
  4. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R, Furukawa K: Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem. 2005 Aug 19;280(33):29828-36. Epub 2005 May 26. [PubMed:15923178 ]
External Links
ATC CodesL01XC16 — Dinutuximab
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (446 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDisseminated Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma1
1Not Yet RecruitingTreatmentNeuroblastomas1
1RecruitingTreatmentRecurrent Neuroblastoma / Stage 4 Neuroblastoma1
1, 2CompletedTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentEffects of Immunotherapy / Neoplasm, Residual / Neuroblastomas1
2RecruitingTreatmentMetastatic Malignant Neoplasm in the Lung / Metastatic Osteosarcoma / Recurrent Osteosarcoma1
2RecruitingTreatmentNeuroblastomas2
2SuspendedTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2TerminatedTreatmentNeuroblastomas1
2Unknown StatusTreatmentNeuroblastoma Recurrent1
2, 3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3Unknown StatusTreatmentNeuroblastomas1
Not AvailableTerminatedNot AvailableNeuroblastomas1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
InjectionIntravenous3.5 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20140170155 No2014-02-182038-02-18Us
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
inhibitor
References
  1. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 1;51(1):144-9. [PubMed:1988079 ]
Drug created on June 18, 2015 11:47 / Updated on November 26, 2016 08:34